ArticleThe Journal of clinical investigation2015

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Coralie Hoareau-Aveilla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.